Auris Medical Holding Ltd. [NASDAQ: EARS] closed the trading session at $3.16 on 03/05/21. The day’s price range saw the stock hit a low of $2.70, while the highest price level was $4.12. The company report on January 29, 2021 that Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis.
Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, announced with its affiliate Altamira Medica AG the initiation of a clinical investigation of AM-301 in allergic rhinitis.
The clinical investigation is an open-label randomized cross-over study that will enroll 36 patients with allergic rhinitis to grass pollen. Study participants will be administered a single dose of AM-301 nasal spray or a comparator product (one puff into each nostril) prior to controlled pollen exposure for four hours in an allergen challenge chamber. The challenge will be repeated with the alternate treatment following a wash-out period. The difference in the Total Nasal Symptom Score (TNSS) between the two treatments over the 4-hour exposure will serve as the primary efficacy endpoint; the investigation shall demonstrate clinical non-inferiority of AM-301 to the comparator product.
The stocks have a year to date performance of 20.61 percent and weekly performance of 3.61 percent. The stock has been moved at 280.72 percent over the last six months. The stock has performed 4.98 percent around the most recent 30 days and changed -9.71 percent over the most recent 3-months.
If compared to the average trading volume of 1.64M shares, EARS reached to a volume of 18683860 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Auris Medical Holding Ltd. [EARS]:
Euro Pacific Capital have made an estimate for Auris Medical Holding Ltd. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 08, 2018. While these analysts kept the previous recommendation, ROTH Capital raised their target price to Buy. The new note on the price target was released on April 13, 2017, representing the official price target for Auris Medical Holding Ltd. stock. Previously, the target price had yet another drop from $11 to $5, while Needham kept a Buy rating on EARS stock.
The Average True Range (ATR) for Auris Medical Holding Ltd. is set at 0.55 The Price to Book ratio for the last quarter was 3.01, with the Price to Cash per share for the same quarter was set at 0.00.
EARS stock trade performance evaluation
Auris Medical Holding Ltd. [EARS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.61. With this latest performance, EARS shares gained by 4.98% in over the last four-week period, additionally plugging by 280.72% over the last 6 months – not to mention a rise of 198.11% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EARS stock in for the last two-week period is set at 48.04, with the RSI for the last a single of trading hit 46.17, and the three-weeks RSI is set at 49.91 for Auris Medical Holding Ltd. [EARS]. The present Moving Average for the last 50 days of trading for this stock 3.09, while it was recorded at 3.10 for the last single week of trading, and 1.63 for the last 200 days.
Auris Medical Holding Ltd. [EARS]: An insightful look at the core fundamentals
Return on Total Capital for EARS is now -128.24, given the latest momentum, and Return on Invested Capital for the company is -134.33. Return on Equity for this stock declined to -134.33, with Return on Assets sitting at -67.22.
Reflecting on the efficiency of the workforce at the company, Auris Medical Holding Ltd. [EARS] managed to generate an average of -$556,116 per employee.Auris Medical Holding Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.20 and a Current Ratio set at 0.20.
Auris Medical Holding Ltd. [EARS]: Insider Ownership positions
There are presently around $1 million, or 1.40% of EARS stock, in the hands of institutional investors. The top three institutional holders of EARS stocks are: VIRTU FINANCIAL LLC with ownership of 63,920, which is approximately New of the company’s market cap and around 6.05% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 63,020 shares of the stock with an approximate value of $0.2 million in EARS stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $69000.0 in EARS stock with ownership of nearly New of the company’s market capitalization.
Positions in Auris Medical Holding Ltd. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 8 institutional holders increased their position in Auris Medical Holding Ltd. [NASDAQ:EARS] by around 184,959 shares. Additionally, 4 investors decreased positions by around 36,941 shares, while 1 investors held positions by with 34,468 shares. The mentioned changes placed institutional holdings at 187,432 shares, according to the latest SEC report filing. EARS stock had 7 new institutional investments in for a total of 183,405 shares, while 3 institutional investors sold positions of 36,865 shares during the same period.